Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto [0.03%]
炎症性肠病患者对从参照产品阿达木单抗转换为阿达木单抗类似药的态度
Catherine Pham,Deana Bitar,Fang Niu et al.
Catherine Pham et al.
Background: There may be patient concerns with switching to a biosimilar product. The purpose of this study was to describe the perspectives of patients with inflammatory bowel diseases (IBD) after switching from referenc...
Ivonescimab in non-small cell lung cancer: harmonizing immunotherapy and anti-angiogenesis [0.03%]
伊沃西单抗在非小细胞肺癌中的应用：协调免疫疗法和抗血管生成治疗
Yan Zhang,Xinyu Liu,Shengxiang Ren
Yan Zhang
Introduction: Immunotherapy combined with anti-angiogenesis has become a useful strategy in cancer treatment. Ivonescimab, the first approved bispecific antibody targeting both immune checkpoint inhibition and anti-angiog...
Management of metastatic melanoma with combinations including PD-1 inhibitors [0.03%]
PD-1抑制剂联合疗法在转移性黑色素瘤中的应用管理
Lara Valeska Maul,Egle Ramelyte,Reinhard Dummer et al.
Lara Valeska Maul et al.
Introduction: Melanoma is among the most immunogenic malignancies. The advent of immune checkpoint inhibitors (ICIs) has revolutionized the landscape of melanoma treatment. Long-term durable cancer control is possible in ...
Biological therapies in thrombocytopenia and primary antiphospholipid syndrome: where are we now? [0.03%]
血小板减少症和原发性抗磷脂综合征中的生物治疗：我们现在处于什么阶段？
Massimo Radin,Alice Barinotti,David Galarza et al.
Massimo Radin et al.
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases [0.03%]
菌群移植和活体生物治疗产品在紊乱相关疾病治疗中的应用
Samantha Flores-Treviño,Paola Bocanegra-Ibarias,Daniel Salas-Treviño et al.
Samantha Flores-Treviño et al.
Introduction: The microbiota composition in humans varies according to the anatomical site and is crucial for maintaining homeostasis and an overall healthy state. Several gastrointestinal, vaginal, respiratory, and skin ...
Islam Eljilany,Julia R Garcia,Basmala Jamal et al.
Islam Eljilany et al.
Introduction: Systemic adjuvant therapy is indicated in patients with high-risk, resected melanoma management to reduce recurrence risk and potentially improve survival rates. Monoclonal antibodies (mAbs) target immune ch...
Incidence of therapy switch in patients with moderate to severe palmoplantar psoriasis treated with anti-IL 17 and anti-IL 23 monoclonal antibodies: a retrospective observational study [0.03%]
接受抗IL 17和抗IL 23单克隆抗体治疗的中重度掌跖银屑病患者换药的发生率：一项回顾性观察研究
Alessandra Michelucci,Flavia Manzo Margiotta,Filippo Fanetti et al.
Alessandra Michelucci et al.
Background: The aim of this study is to confront the effectiveness of anti-IL 17 versus anti-IL 23 mAb in treating palmoplantar psoriasis by comparing the incidence of patients that required a therapy switch to another mA...
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-hodgkin lymphoma [0.03%]
评估Odronextamab治疗多种类型的复发/难治性B细胞非霍奇金淋巴瘤的疗效
Elena Bayly-McCredie,Henry Miles Prince,Costas Kleanthes Yannakou et al.
Elena Bayly-McCredie et al.
Introduction: Patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) have a poor median survival rate when treated with traditional salvage therapies. Bispecific antibodies (BsAbs) are an emerging class of ...
Ashish Sharma,Se Joon Woo,Baruch D Kuppermann
Ashish Sharma
IL23p19 therapies for moderately-to-severely active ulcerative colitis [0.03%]
IL23p19治疗中至重度活动性溃疡性结肠炎
Newaz Shubidito Ahmed,Christopher Ma
Newaz Shubidito Ahmed
Introduction: Ulcerative colitis (UC) is a chronic, relapsing and remitting, inflammatory bowel disease. Monoclonal antibodies targeting interleukin (IL)-23p19 have been developed to treat chronic inflammatory diseases me...